Matthew J. Frigault, MD

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss questions ongoing research with CAR T-cell therapy in multiple myeloma aims to address.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail key CAR T-cell therapy data in multiple myeloma from ASH 2025.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss potential targets for novel CAR T-cell therapies in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss findings from the iMMagine-1 of anito-cel in relapsed/refractory multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss the investigational CAR T-cell therapy anito-cel in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, explain the role of bridging therapy alongside CAR T-cell therapy in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail the drive beyond additional CAR T-cell therapy research in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss treatment approaches in fourth- and later-line multiple myeloma.

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.